Dolby Laboratories (DLB)
Official siteINDUSTRIALS • SPECIALTY BUSINESS SERVICES • NYSE
Market Cap: $5.96B
Last updated: Nov 17, 2026 at 11:04 AM ET
Dolby Laboratories (DLB) Financials: Revenue, Profit and Cash Flow
Dolby Laboratories reported revenue of $1.35B for the fiscal year ended Sep 30, 2025, up 5.9% from the year before. That year, net income was $256.49M with a net margin of 19.0%, operating cash flow was $472.20M and free cash flow was $435.85M. The quarter ended Jun 30, 2026 had revenue of $305.00M and net income of $29.21M.
Revenue and Margins
The operating margin was 19.6% in the fiscal year ended Sep 2025. Over the 9 years to Sep 2025, revenue grew from $1.03B, a compound annual rate of 3.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $1.35B | +5.9% | 88.1% | 19.6% | 19.0% |
| Sep 2024 | $1.27B | -2.0% | 89.0% | 20.3% | 20.8% |
| Sep 2023 | $1.30B | +3.7% | 88.3% | 16.6% | 15.5% |
| Sep 2022 | $1.25B | -2.1% | 88.7% | 16.5% | 14.7% |
| Sep 2021 | $1.28B | +10.3% | 89.9% | 26.9% | 24.8% |
| Sep 2020 | $1.16B | -6.4% | 87.4% | 18.8% | 19.9% |
| Sep 2019 | $1.24B | -41.1% | 87.0% | 20.7% | 20.6% |
| Sep 2018 | $2.11B | -2.4% | 87.9% | 8.7% | 2.0% |
| Sep 2017 | $2.16B | +110.6% | 89.0% | 11.4% | 9.6% |
| Sep 2016 | $1.03B | N/A | 89.4% | 22.6% | 18.2% |
Income Statement
In the fiscal year ended Sep 2025, net income fell 3.0% from the year before. In the quarter ended Jun 2026, net income fell 37.2% from the same quarter a year earlier.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.35B | $1.27B | $1.30B | $1.25B | $1.28B | $1.16B | $1.24B | $2.11B | $2.16B | $1.03B |
| Cost of revenue | $160.13M | $140.50M | $152.57M | $141.36M | $130.03M | $146.50M | $160.85M | $255.12M | $237.06M | $108.98M |
| Gross profit | $1.19B | $1.13B | $1.15B | $1.11B | $1.15B | $1.02B | $1.08B | $1.85B | $1.92B | $916.76M |
| Research and development | $261.79M | $263.66M | $271.52M | $261.17M | $253.64M | $239.04M | $237.87M | $236.79M | $233.31M | $219.61M |
| Operating income | $264.96M | $258.33M | $215.75M | $206.60M | $344.39M | $218.74M | $257.08M | $183.50M | $247.13M | $231.79M |
| Net income | $256.49M | $264.32M | $201.64M | $183.90M | $317.82M | $231.62M | $255.50M | $42.30M | $207.11M | $186.40M |
| EBITDA | $386.71M | $362.81M | $316.62M | $314.15M | $465.63M | $339.86M | $343.04M | $261.36M | $332.76M | $319.32M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $305.00M | $395.63M | $346.71M | $307.02M | $315.55M | $369.56M | $357.00M | $304.81M | $288.82M | $364.52M | $315.57M | $290.56M |
| Gross profit | $264.68M | $350.90M | $303.50M | $267.50M | $271.54M | $333.72M | $316.23M | $270.81M | $253.16M | $325.75M | $283.51M | $255.01M |
| Operating income | $34.32M | $112.95M | $62.16M | $29.68M | $47.64M | $107.76M | $79.88M | $46.35M | $36.78M | $108.97M | $66.22M | -$3.49M |
| Net income | $29.21M | $95.45M | $53.68M | $49.65M | $46.54M | $92.23M | $68.07M | $58.87M | $39.66M | $98.21M | $67.58M | $9.91M |
Balance Sheet
As of Sep 2025, cash and equivalents exceeded short-term debt of $10.38M by $691.51M.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.23B | $3.11B | $2.98B | $2.69B | $3.11B | $2.92B | $2.82B | $2.87B | $2.53B | $2.31B |
| Current assets | $1.39B | $1.19B | $1.49B | $1.31B | $1.76B | $1.55B | $1.38B | $1.50B | $1.01B | $759.73M |
| Cash and equivalents | $701.89M | $482.05M | $745.36M | $620.13M | $1.23B | $1.07B | $797.21M | $918.06M | $627.02M | $516.11M |
| Total liabilities | $595.81M | $623.03M | $607.58M | $438.53M | $501.45M | $478.92M | $508.72M | $494.88M | $389.71M | $331.37M |
| Short-term debt | $10.38M | $12.24M | $13.63M | $13.26M | $15.40M | $15.82M | $0 | $0 | $0 | $0 |
| Shareholder equity | $2.62B | $2.48B | $2.36B | $2.25B | $2.60B | $2.43B | $2.31B | $2.36B | $2.14B | $1.97B |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.16B | $3.25B | $3.19B | $3.23B | $3.20B | $3.23B | $3.16B | $3.13B | $2.97B | $3.04B | $2.94B | $2.99B |
| Total liabilities | $563.89M | $622.36M | $589.25M | $595.81M | $581.75M | $646.02M | $641.57M | $643.72M | $526.20M | $607.04M | $573.22M | $622.38M |
| Cash and equivalents | $669.39M | $594.28M | $643.85M | $701.89M | $698.57M | $626.55M | $520.82M | $577.75M | $741.64M | $709.53M | $656.82M | $817.97M |
| Shareholder equity | $2.58B | $2.62B | $2.59B | $2.62B | $2.60B | $2.57B | $2.51B | $2.48B | $2.43B | $2.42B | $2.35B | $2.36B |
Cash Flow
In the fiscal year ended Sep 2025, free cash flow was 92.3% of operating cash flow. Dividends and share repurchases together came to 66.8% of it.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $472.20M | $327.25M | $367.08M | $318.58M | $447.75M | $343.85M | $327.67M | $352.20M | $377.79M | $360.06M |
| Capital expenditures | $36.35M | $30.01M | $30.34M | $47.93M | $54.45M | $66.35M | $96.28M | $72.81M | $99.62M | $100.76M |
| Free cash flow | $435.85M | $297.25M | $336.74M | $270.65M | $393.30M | $277.50M | $231.39M | $279.39M | $278.18M | $259.30M |
| Dividends paid | $128.45M | $129.66M | $103.67M | $101.50M | $96.53M | $88.86M | $78.51M | $67.18M | $59.15M | $48.61M |
| Share repurchases | $162.49M | $199.08M | $180.42M | $566.90M | $278.07M | $196.81M | $363.37M | $172.61M | $117.68M | $114.49M |
| Investing cash flow | -$10.59M | -$286.29M | $54.21M | -$295.94M | -$44.91M | $134.37M | -$56.23M | $78.09M | -$158.03M | -$282.50M |
| Financing cash flow | -$247.24M | -$287.81M | -$236.81M | -$610.56M | -$252.51M | -$207.78M | -$385.28M | -$133.63M | -$106.83M | -$91.99M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $167.46M | $92.51M | $54.80M | $122.83M | $67.69M | $174.90M | $106.78M | $116.17M | $21.26M | $181.41M | $8.41M | $85.02M |
| Capital expenditures | $14.99M | $9.06M | $4.63M | $16.24M | $6.43M | $6.90M | $6.78M | $7.38M | $7.61M | $8.92M | $6.10M | $8.19M |
| Free cash flow | $152.47M | $83.44M | $50.17M | $106.59M | $61.26M | $168.00M | $100.00M | $108.79M | $13.65M | $172.49M | $2.31M | $76.83M |
Frequently Asked Questions About DLB
What is Dolby Laboratories' annual revenue?
Dolby Laboratories reported revenue of $1.35B for the fiscal year ended Sep 30, 2025.
How fast is Dolby Laboratories' revenue growing?
Revenue was up 5.9% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.5%.
Is Dolby Laboratories profitable?
Yes. Dolby Laboratories reported net income of $256.49M for the fiscal year ended Sep 30, 2025, with a net margin of 19.0%.
How much free cash flow does DLB generate?
For the fiscal year ended Sep 30, 2025, operating cash flow of $472.20M minus capital expenditures of $36.35M produced free cash flow of $435.85M.
How much debt does Dolby Laboratories have?
The balance sheet dated Sep 30, 2025 reported short-term debt of $10.38M and cash and equivalents of $701.89M.
DLB pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors